A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma
Castrate Resistant Prostate Cancer
Hormone Receptor Positive HER2 Negative Breast Cancer
Non-small Cell Lung Cancer
Solid Tumors With Known MYC Amplification

Interventions

DRUG: PRT2527

Sponsor

Prelude Therapeutics